A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
improve the treatment of rare diseases and conditions, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Helping Experts Accel-
4
erate Rare Treatments Act of 2022’’. 
5
SEC. 2. IMPROVING THE TREATMENT OF RARE DISEASES 
6
AND CONDITIONS. 
7
(a) ANNUAL REPORT
ON ORPHAN DRUG PRO-
8
GRAM.—Subchapter B of chapter V of the Federal Food, 
9
06:00 Apr 07, 2022
H6888
2 
•HR 6888 IH
Drug, and Cosmetic Act (21 U.S.C. 360aa et seq.) is 
1
amended by adding at the end the following new section: 
2
‘‘SEC. 529B. ANNUAL REPORT ON ORPHAN DRUG PROGRAM. 
3
‘‘(a) IN GENERAL.—Not later than the end of each 
4
of the 4 years following the date of enactment of the Help-
5
ing Experts Accelerate Rare Treatments Act of 2022, the 
6
Secretary shall submit to the Congress a report summa-
7
rizing the activities of the Food and Drug Administration 
8
related to designating drugs under section 526 for a rare 
9
disease or condition and approving such drugs under sec-
10
tion 505 of this Act or licensing such drugs under section 
11
351 of the Public Health Service Act, including— 
12
‘‘(1) the number of applications for such drugs 
13
under section 505 of this Act and section 351 of the 
14
Public Health Service Act received by the Food and 
15
Drug Administration, the number of such applica-
16
tions accepted and rejected for filing, and the num-
17
ber of such applications pending, approved, and dis-
18
approved by the Food and Drug Administration, 
19
arrayed by the review division assigned to the appli-
20
cation; and 
21
‘‘(2) assess the extent to which the Food and 
22
Drug Administration is consulting with external ex-
23
perts pursuant to section 569(a)(2) on topics per-
24
taining to drugs for a rare disease or condition, in-
25
06:00 Apr 07, 2022
H6888
3 
•HR 6888 IH
cluding how and when any such consultation is oc-
1
curring. 
2
‘‘(b) PUBLIC AVAILABILITY.—The Secretary shall 
3
make each report under subsection (a) available to the 
4
public, including by posting the report on the website of 
5
the Food and Drug Administration. 
6
‘‘(c) DEFINITION.—In this section, the term ‘rare 
7
disease or condition’ means a disease or condition affect-
8
ing fewer than 200,000 persons in the United States.’’. 
9
(b) STUDY ON EUROPEAN UNION SAFETY AND EFFI-
10
CACY REVIEWS OF DRUGS FOR RARE DISEASES AND CON-
11
DITIONS.— 
12
(1) IN GENERAL.—The Comptroller General of 
13
the United States shall enter into a contract with an 
14
appropriate entity to conduct a study on the Euro-
15
pean Union process for evaluating the safety and ef-
16
ficacy of drugs for rare diseases or conditions, in-
17
cluding— 
18
(A) any flexibilities, authorities, or mecha-
19
nisms available in the European Union specific 
20
to rare diseases or conditions; and 
21
(B) consideration and use of supplemental 
22
data submitted during the review process, in-
23
cluding data associated with open label exten-
24
06:00 Apr 07, 2022
H6888
4 
•HR 6888 IH
sion studies and expanded access programs spe-
1
cific to rare diseases or conditions. 
2
(2) CONSULTATION.—The contract under para-
3
graph (1) shall provide for consultation with relevant 
4
stakeholders, including— 
5
(A) rare disease or condition patients; and 
6
(B) patient groups that— 
7
(i) represent rare disease or condition 
8
patients; and 
9
(ii) have international patient out-
10
reach. 
11
(3) REPORT.—The contract under paragraph 
12
(1) shall provide for— 
13
(A) not later than 2 years after the date 
14
of enactment of this Act— 
15
(i) the completion of the study under 
16
paragraph (1); and 
17
(ii) the submission of a report on the 
18
results of such study to the Congress; and 
19
(B) the inclusion in the report under sub-
20
paragraph (A)(ii) of recommendations for 
21
changes to the processes and authorities of the 
22
Food and Drug Administration to facilitate de-
23
velopment of, and access to, treatments for rare 
24
diseases or conditions. 
25
06:00 Apr 07, 2022
H6888
5 
•HR 6888 IH
(4) PUBLIC AVAILABILITY.—The contract under 
1
paragraph (1) shall provide for the appropriate enti-
2
ty referred to in paragraph (1) to make the report 
3
under paragraph (3) available to the public, includ-
4
ing by posting the report on the website of the ap-
5
propriate entity. 
6
(c) PUBLIC MEETING.— 
7
(1) IN GENERAL.—Not later than December 31, 
8
2023, the Secretary of Health and Human Services, 
9
acting through the Commissioner of Food and 
10
Drugs, shall convene one or more public meetings to 
11
solicit input from stakeholders regarding the ap-
12
proaches described in paragraph (2). 
13
(2) APPROACHES.—The public meeting or 
14
meetings under paragraph (1) shall address ap-
15
proaches to increasing and improving engagement 
16
with rare disease or condition patients, groups rep-
17
resenting such patients, rare disease or condition ex-
18
perts, and experts on small population studies, in 
19
order to improve the understanding with respect to 
20
rare diseases or conditions of— 
21
(A) patient burden; 
22
(B) treatment options; and 
23
(C) side effects of treatments, including— 
24
06:00 Apr 07, 2022
H6888
6 
•HR 6888 IH
(i) comparing the side effects of treat-
1
ments; and 
2
(ii) understanding the risks of side ef-
3
fects relative to the health status of the pa-
4
tient and the progression of the disease or 
5
condition. 
6
(3) PUBLIC DOCKET.—The Secretary of Health 
7
and Human Services shall establish a public docket 
8
to receive written comments related to the ap-
9
proaches addressed during each public meeting 
10
under paragraph (1). Such public docket shall re-
11
main open for 60 days following the date of each 
12
such public meeting. 
13
(4) REPORTS.—Not later than 180 days after 
14
each public meeting under paragraph (1), the Com-
15
missioner of Food and Drugs shall develop and pub-
16
lish on the website of the Food and Drug Adminis-
17
tration a report on— 
18
(A) the approaches discussed at the public 
19
meeting; and 
20
(B) any related recommendations. 
21
(d) CONSULTATION
ON
THE SCIENCE
OF SMALL 
22
23
Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–8(b)) 
24
is amended by adding at the end the following: 
25
06:00 Apr 07, 2022
H6888
7 
•HR 6888 IH
‘‘(C) SMALL POPULATION STUDIES.—The 
1
external experts on the list maintained pursuant 
2
to subparagraph (A) may include experts on the 
3
science of small population studies.’’. 
4
(e) STUDY
ON SUFFICIENCY
AND USE
OF FDA 
5
MECHANISMS FOR INCORPORATING THE PATIENT AND 
6
CLINICIAN PERSPECTIVE IN FDA PROCESSES RELATED 
7
TO APPLICATIONS CONCERNING DRUGS FOR RARE DIS-
8
EASES OR CONDITIONS.— 
9
(1) IN GENERAL.—The Comptroller General of 
10
the United States shall conduct a study on the use 
11
of Food and Drug Administration mechanisms and 
12
tools to ensure that patient and physician perspec-
13
tives are considered and incorporated throughout the 
14
processes of the Food and Drug Administration— 
15
(A) for approving or licensing under sec-
16
tion 505 of the Federal Food, Drug, or Cos-
17
metic Act (21 U.S.C. 355) or section 351 of the 
18
Public Health Service Act (42 U.S.C. 262) a 
19
drug designated as a drug for a rare disease or 
20
condition under section 526 of the Federal 
21
Food, Drug, and Cosmetic Act (21 U.S.C. 
22
360bb); and 
23
06:00 Apr 07, 2022
H6888
8 
•HR 6888 IH
(B) in making any determination related 
1
to such a drug’s approval, including assessment 
2
of the drug’s— 
3
(i) safety or effectiveness; or 
4
(ii) postapproval safety monitoring. 
5
(2) TOPICS.—The study under paragraph (1) 
6
shall— 
7
(A) identify and compare the processes 
8
that the Food and Drug Administration has 
9
formally put in place and utilized to gather ex-
10
ternal expertise (including patients, patient 
11
groups, and physicians) on specific applications 
12
for diseases or conditions affecting 20,000 or 
13
fewer patients in the United States and specific 
14
applications for diseases or conditions affecting 
15
200,000 or fewer patients in the United States; 
16
(B) examine tools or mechanisms to im-
17
prove efforts and initiatives of the Food and 
18
Drug Administration to collect and consider 
19
such external expertise with respect to applica-
20
tions for diseases or conditions affecting 20,000 
21
or fewer patients in the United States com-
22
pared to applications for diseases or conditions 
23
affecting 200,000 or fewer patients in the 
24
United States throughout the application review 
25
06:00 Apr 07, 2022
H6888
9 
•HR 6888 IH
and approval or licensure processes, including 
1
within internal benefit-risk assessments, advi-
2
sory committee processes, and postapproval 
3
safety monitoring; and 
4
(C) examine processes or alternatives to 
5
address or resolve conflicts of interest that im-
6
pede the Food and Drug Administration in 
7
gaining external expert input on rare diseases 
8
or conditions with a limited set of clinical and 
9
research experts. 
10
(3) REPORT.—Not later than 2 years after the 
11
date of enactment of this Act, the Comptroller Gen-
12
eral of the United States shall— 
13
(A) complete the study under paragraph 
14
(1); 
15
(B) submit a report on the results of such 
16
study to the Congress; and 
17
(C) include in such report recommenda-
18
tions, if appropriate, for changes to the proc-
19
esses and authorities of the Food and Drug Ad-
20
ministration to improve the collection and con-
21
sideration of external expert opinions of pa-
22
tients, patient groups, and physicians with ex-
23
pertise in rare diseases or conditions, including 
24
any specific recommendations for diseases or 
25
06:00 Apr 07, 2022
H6888
10 
•HR 6888 IH
conditions affecting 20,000 or fewer patients in 
1
the United States. 
2
(f) DEFINITION.—In this section, the term ‘‘rare dis-
3
ease or condition’’ means a disease or condition affecting 
4
fewer than 200,000 persons in the United States. 
5
Æ 
06:00 Apr 07, 2022
H6888
